Skip to main content

What the FDA labels say about taking them together

Mifepristone and rifabutin

Mifepristone's FDA label of September 25, 2025 names rifabutin in its drug interactions section; the rifabutin label PlainMeds reads does not name mifepristone. The mifepristone label: “Avoid co-administration of mifepristone and CYP3A inducers such as rifampin, rifabutin, rifapentin, phenobarbital, phenytoin, carbamazepine, and St. John's wort.”

Check it at the source: the mifepristone FDA label on DailyMed (effective September 25, 2025, Corcept Therapeutics Incorporated); the rifabutin FDA label on DailyMed (effective September 1, 2026, REMEDYREPACK INC.).

What does the mifepristone label say about rifabutin?

Mifepristone label, drug interactions

Avoid co-administration of mifepristone and CYP3A inducers such as rifampin, rifabutin, rifapentin, phenobarbital, phenytoin, carbamazepine, and St. John's wort.

Source: FDA drug label (Mifepristone), Corcept Therapeutics Incorporated, effective September 25, 2025 (SPL set 63c068cd-9370-460f-829b-70e8c7ebe91e), via openFDA; the full label on DailyMed

What does the rifabutin label say about mifepristone?

Rifabutin's label (effective September 1, 2026) does not name mifepristone in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Rifabutin), NDA050689 (Pfizer), as published by REMEDYREPACK INC., effective September 1, 2026 (SPL set 25a60937-cbbe-4a50-994f-2ce15203f589), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

3Mifepristone generic labelers
4Rifabutin generic labelers
MifepristoneRifabutin
Labeled forn/an/a
Boxed warningYesNo
Pharmacy cost (NADAC)n/a$8.14 per capsule 150 mg capsule
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?